Free Trial
Your Rate Never Goes Up! Save $100 a Year on MarketBeat All Access
Upgrade Now
Claim MarketBeat All Access Sale Promotion
NASDAQ:BDSX

Biodesix Q3 2026 Earnings Date & Estimates

Biodesix logo
$21.26 +0.08 (+0.38%)
Closing price 04:00 PM Eastern
Extended Trading
$21.29 +0.03 (+0.14%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biodesix is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Biodesix in Q3 2026

Biodesix is expected to post earnings of -$0.75 per share on revenue of $27.56 million. In the same quarter a year earlier Biodesix reported -$1.16 per share on revenue of $21.77 million. Biodesix last reported on August 5, 2026, posting -$0.71 per share and beating the -$0.9018 consensus estimate. Biodesix has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.75
Expected Revenue
$27.56 million
Prior-Year EPS
-$1.16
Prior-Year Revenue
$21.77 million
Expected Revenue Growth
+26.6%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.71 (Beat by +$0.1918)
Last Quarter Revenue
$26.86 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Biodesix Q3 2026 Earnings FAQ

Biodesix (NASDAQ:BDSX) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Biodesix's Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Biodesix to post earnings of -$0.75 per share for Q3 2026.

The consensus revenue estimate for Biodesix is $27.56 million for Q3 2026.

Biodesix Earnings Headlines

Biodesix, Inc. to Report Third Quarter 2026 Financial Results on November 5
October 22, 2026  |  quiverquant.comQ
Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026
October 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/22/3386127/0/en/biodesix-to-report-third-quarter-2026-financial-results-on-november-5-2026.html
Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.tc pixel
October 26 at 1:00 AM  |  Weiss Ratings (Ad)
Biodesix, Inc. Adds Digital Diagnostics to Lung Diagnostics Strategy and Develops Radiomics-Based Test for Lung Nodule Risk Assessment
October 19, 2026  |  marketscreener.comM
American College of Chest Physicians Publishes New Framework for Lung Nodule Programs Recommending Biomarkers for Risk Stratification
October 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/19/3383858/0/en/american-college-of-chest-physicians-publishes-new-framework-for-lung-nodule-programs-recommending-biomarkers-for-risk-stratification.html
Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers
October 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/19/3383136/0/en/biodesix-adds-digital-diagnostics-to-lung-pipeline-creating-new-growth-platform-combining-blood-and-imaging-biomarkers.html
See More Biodesix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biodesix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biodesix and other key companies, straight to your email.

About Biodesix

Biodesix (NASDAQ:BDSX) is a data-driven diagnostic solutions company focused on improving the diagnosis and treatment of lung diseases, including lung cancer. The company combines proprietary molecular diagnostic technologies, clinical data, and artificial intelligence to help physicians assess disease risk and make more informed treatment decisions.

Its offerings include blood-based tests designed to help evaluate indeterminate pulmonary nodules, identify patients who may be at higher risk of lung cancer, and support treatment selection and monitoring. Biodesix also provides molecular testing services and data analytics for pharmaceutical and biotechnology companies conducting clinical research and developing targeted therapies.

Biodesix serves healthcare providers, laboratories, biopharmaceutical companies, and research organizations, primarily in the United States. The company was founded in 2005 and is headquartered in Boulder, Colorado. Its shares trade on the Nasdaq under the symbol BDSX.

View Biodesix Profile
Earnings Tools